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Abstract  
Background: Mutations of the epidermal growth factor receptor (EGFR) are a possible molecular 
target for cancer therapy. EGFR is frequently amplified in glioblastomas and 30 to 40% of  
glioblastomas also express the deletion mutation EGFRvIII. This frequent oncogenic mutation 
provides an opportunity for identifying new anti-glioblastoma therapies. In this study, we sought 
small molecule inhibitors specific for cancer cells expressing EGFRvIII, using isogenic parental cells 
without EGFRvIII as a control. 
Results: A screen of the NCI small molecule diversity set identified one compound, NSC-154829, 
which consistently inhibited growth of different human glioblastoma cells expressing EGFRvIII, but 
permitted normal growth of matched control cells. NSC-154829 had no previously established 
medicinal use, but has a purine-like structural component. Further experiments showed this  
compound increased apoptosis in cells with EGFRvIII, and moderately affected the expression of  
p21, independent of any changes in p53 levels or in Akt phosphorylation. 
Conclusion: These initial results suggest that NSC-154829 or a closely related structure might be 
further investigated for its potential as an anti-glioblastoma drug, although its precise molecular 
mechanism is still undefined. 
Background 
The epidermal growth factor receptor (EGFR), a type I  
tyrosine kinase receptor, has been associated with numer-
ous malignancies including breast, lung, head and neck,  
bladder, colorectal, ovarian, and prostate carcinomas, as  
well as with the most common form of brain tumor,  
glioblastoma [1]. Several small molecules have been  
developed to target EGFR including gefitinib (Iressa) and 
erlotinib (Tarceva), which interfere with ATP-binding and 
tyrosine kinase activity. EGFR inhibitors have shown  
promise and extended patient survival in lung, pancreatic  
and other cancers, however, survival gains are often mod-
est, and, in non-small-cell lung cancers, activity is limited  
to the approximately 10% of patients with small activat-
ing mutations in the EGFR tyrosine kinase domain [2,3].  
It also appears that subsequent mutations at different  




Molecular Cancer 2007, 6:30 http://www.molecular-cancer.com/content/6/1/30 
Targeting EGFR in glioblastomas has the additional chal-
lenge of the expression of EGFRvIII (epidermal growth  
factor receptor variant type III; also named de2-7 EGFR 
and deltaEGFR). EGFRvIII is found in 67% of tumors with 
amplified EGFR [5] and reported in 38% of all glioblasto-
mas [6]. There has been recent evidence that EGFRvIII is  
also present in a minority (5%) of squamous cell lung  
cancers [7]. EGFRvIII is a deletion between exons 2–7 of 
the EGFR gene with loss of 267 amino acids from the  
extracellular domain, creating a constitutively active ver-
sion of the protein [8]. EGFRvIII exists at high frequency  
in glioblastomas, and according to some reports imparts a  
worse prognosis and confers therapeutic resistance [9-13]. 
Our earlier work demonstrated that EGFRvIII expression  
in glioblastoma cells increased cellular motility and in  
vitro invasiveness [ 14]. In terms of current EGFR therapies, 
the picture in regards to glioblastomas is mixed. The  
kinase domain mutations correlated with gefitinib  
response are infrequent in glioblastomas and phase II tri-
als of gefitinib showed no survival benefit in glioblastoma 
[15,16]. Yet, in a more recent study, tumors with both  
EGFRvIII and PTEN mutations responded better to EGFR 
inhibitors erlotinib or gefitinib [17]. However, since the  
present EGFR inhibitors have, at best, a small survival  
benefit in glioblastomas and as their use may select for  
further resistance-conferring mutations, there is utility in 
identifying additional compounds that can specifically  
inhibit cells with the EGFRvIII mutation. 
To find new inhibitors of glioblastoma cells expressing  
EGFRvIII, we used an isogenic cell-based approach for  
screening small molecule libraries [18]. For this study we  
stably transfected an established glioblastoma cell line  
with EGFRvIII using antibiotic selection. Generally, gliob-
lastoma cell lines lose their native EGFRvIII over time  
when passaged in vitro, making it necessary to replace this 
oncogene to study it in vitro. The two isogenic cell lines  
(with and without EGFRvIII) were transfected with yellow  
or blue fluorescent protein respectively, and then these  
different fluorescent markers were used to independently  
track the growth of the two cell lines. Individual diverse  
small molecules were dissolved in the media of different  
multititer plate wells, each containing an identical co-cul-
ture of the mutant and control cells. In vitro growth of 
each cell line, and its response to the different small mol-
ecules, was monitored by measuring fluorescence levels  
over one week. In this manner, compounds that specifi-
cally inhibit the growth of the mutant-containing cell line 
were identified (see Figure 1). We applied this isogenic  
cell line screening strategy to the National Cancer Insti-
tute's diversity set of 1,990 small molecules to identify  
growth inhibitors of EGFRvIII-containing cells. 
Results 
Identification of NSC-154829 
Our primary small molecule screen identified 118 com-
pounds with one of three properties: 1) inhibition of both  
cell lines, 2) preferential inhibition of one cell line, or 3)  
stimulation of both cell lines. Figure 2a–c shows examples 
of non-selective and selective inhibition (b and c respec-
tively) contrasted with an example of non-inhibition (a).  
Of the 1,990 compounds, 118 (6%) had an observable  
effect on cell growth at 2 µM, a result similar to the 5.7% 
reported for the screen of K-Ras inhibitors [18]. These 118 
compounds were re-screened at concentrations ranging  
from 0.03 to 4 gM to determine if there was a dose- 
dependent effect on the EGFRvIII-containing cell line  
(Figure 2d–f). In this secondary screen, 36 compounds  
inhibited both cell lines across different concentrations,  
and of these, 15 demonstrated a preferential inhibition of  
the EGFRvIII cell line in the primary screen. Accordingly,  
these 15 inhibitory compounds were submitted to a terti-
ary screen, but now against two different subclones of the  
897 (control) and 898 (EGFRvIII) cell lines. Seven com-
pounds that did not inhibit all of the 898 subclones were  
eliminated. The remaining eight compounds consistently  
and preferentially inhibited growth of the 898 cell lines  
and did not inhibit growth of the 897 cell lines. 
Verification of NSC-154829's selectivity against EGFRvIII + 
cells 
To insure that the selectivity against cells expressing  
EGFRvIII was not a function of genetic background, two 
additional tests were performed on the remaining eight  
compounds: 1) the compounds were tested against addi-
tional 897 and 898 subclones (again transfected with blue  
and yellow fluorescent protein respectively), to determine  
if there were consistent significant difference in IC50s  
between the wild type and mutant cells and 2) the com-
pounds were tested against a different glioma cell line,  
D54 and D54E, the latter transfected with EGFRvIII. Test-
ing using different 897/898 subclones was performed  
using the same fluorescent screen as described earlier. IC50 
values for one of the compounds, NSC-154829, are  
shown in Table 1; for each set of subclones, there was a 
significant lower IC50 for the 898 cells compared to the  
897s. For testing the compounds against the D54 and 54E  
cell lines, cells were plated in individual wells and treated  
with the eight compounds that demonstrated preferential  
activity against the 898 cells. Growth was measured using  
a SybrGreen fluorescence assay [19]. Using this approach,  
NSC-154829 was the sole compound out of the original  
1,990 that consistently showed preferential inhibition of  
EGFRvIII + cell lines in both the 897/898 and D54/54E 
systems. Figure 3 shows the preferential inhibition of one  
of the 898 subclones (a), the significant decrease in cell  
growth for the D54E cell line at 2 gM (b), and the struc-
ture of NSC-154829 (c). D54E also demonstrated a signif- 
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Relative purity of NSC-154829 
The relative purity of small molecules from the NCI  
library with selective activity against 898 cells was assessed  
by HPLC, since degradation is a potential problem in  
chemical libraries. NSC-154829 demonstrated 82%  
purity, using an area-under-the-curve analysis. 
NSC-154829's effects on cell growth 
Trypan blue studies were performed on 897 and 898 cells 
treated with 2 gM of NSC-154829. The percentage of dead 
cells remained similar between treated cell lines versus  
controls during the first 24–48 hours following treatment; 
however, at 48 hours, the percentage of dead cells present  
in the EGFRvIII+ cell line increased dramatically and sig-
nificantly over wild-type (see Figure 4a). Hoechst staining  
of treated cells, examined on days 0–3, showed a signifi-
cant increase in the number of apoptotic nuclei in the  
EGFRvIII + cells compared to controls (see Figure 4b). 
NSC-154829's effects on apoptosis 
To verify that the cell death measured in our fluorescence  
and trypan blue studies were due to apoptosis, we investi-
gated if treatment with NSC-154829 resulted in an  
increase in caspases, important mediators of apoptosis in 
mammalian cells [20,21]. As shown in Figure 5a, treat-
ment of 898 subclones with as little as 1 gM of NSC-
154829 increased caspase 3/7 activity 1.5 fold over treat-
ment with the carrier molecule (DMSO) alone. Similar  
treatments of the EFGR wild type cell line (897) produced  
no detectable difference in caspase levels compared to  
controls (Figure 5a). These changes were seen across dif-
ferent 897/898 subclones (data not shown). To insure  
that the presence of the fluorescent proteins was not inter-
fering with the caspase assay, similar experiments were  
performed with D54 and D54E. Treatment with 1 gM 
NSC-154829 produced minimally increased caspase lev-




(Figure 5b). However, 5 M and 10 M of NSC-154829   
produced corresponding increases in caspase activity in   
the EGFRvIII+ cells and minimal, if any, changes in cas-  
pase levels in the wild-type cell line (see Figure 5c and 5d).  
Thus, the selective inhibition of cell growth in the   
EGFRvIII+ cell lines would appear to be due, in part, to   
increasing levels of apoptosis in the mutant cell lines.  
NSC-154829's effects on phosphorylated Akt (Ser473) 
Studies of glioblastomas and EGFR have focused on the  
effects EGFRvIII has in up-regulating the PI3K/Akt path-
way as the mechanism behind the tumorigenicity of  
EGFRvIII [22,23]. Inhibition of Akt phosphorylation,  
whether by Akt kinase inhibitors or anti-sense oligonucle-
otides, has shown promise in limiting tumor growth,  
including glioblastomas [24,25]. Thus, we analyzed NSC-
154829's effects the phosphorylation of the serine 473  
residue of Akt in our cell lines via Western blot. The 898  
cell line shows mildly increased P-Akt levels in normal  
conditions (10% serum) and the absence of drug. Treat- 
ment with 2 M of NSC-154829 produced minimal   
changes in P-Akt levels in both the wild type and mutant  
cells (data not shown). 
It has been previously demonstrated that EGFRvIII is nec-
essary for glioma cell proliferation under serum starvation 
conditions and that this proliferation is dependent on  
PI3K/P-Akt signaling [23,26]. When we subjected our  
897/898 cell lines to serum starvation (0.5% serum), P- 
Akt levels were up-regulated in both the wild-type and 
mutant cell lines (see Figure 6a, lanes 1 and 2). When  
treated with NSC-154829, there is a dose-response effect, 
with increasing amounts of NSC-154829 (2 M in Figure 
6a, lanes 3 and 4; 5 M Figure lanes 5 and 6) leading to a 
corresponding decrease in expression of P-Akt. When 897 
or 898 cells are exposed to EGF (final concentration 100 
ng/mL) there is, not surprisingly, increased expression of  
P-Akt (Figure 6a, lanes 7 and 8) in both cell lines. Simi-
larly, this increased expression is mildly abrogated by 2  
M of NSC-154829 in both the wild type and mutant cells 
(Figure 6a, lanes 9 and 10). 
NSC-154829's effects on P-Akt expression in the glioma  
cell line D54/54E was more pronounced, but similar in  
both cell lines. There was minimal effect on P-Akt expres-
sion under conditions of 10% serum (data not shown).  
When the D54/54E cells were stressed, via exposure to  
0.5% serum, P-Akt levels increased dramatically and the 
increase in P-Akt in both cell lines was decreased by expo- 
sure to 2 M NSC-154829 (data not shown). This effect,  
however, was not consistent, with the decrease in P-Akt 
often greater in the wild-type cell line versus mutant as 
levels of NSC-154829 increased from 2 to 5 M. Applica 
tion of EGF (100 ng/mL) did not produce as profound an  
increase in P-Akt compared to the 897/898 cell lines and,  
again, application of NSC-154829 did not consistently  
decrease P-Akt expression in the mutant compared to the  
wild-type cell line. Given these results, it appears that  
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NSC-154829's selective effect on the EGFRvIII+ cells is not 
mediated through P-Akt or intermediary signaling mole-
cules between the receptor and P-Akt. 
NSC-154829's effects on the p53/p21 pathway 
As it did not appear that NSC-154829 was acting selec-
tively through the P-Akt pathway, we next studied the p53 
pathway which is also frequently mutated in glioblasto-
mas, particularly in "secondary" glioblastomas, which  
develop from low grade astrocytomas (WHO grade II) to 
anaplastic astrocytomas (WHO grade III) and finally to  
glioblastomas (WHO grade IV) [27]. The increased cas-
pase activity seen in the EGFRvIII+ cells also suggested this 
pathway, given p53's role in apoptosis regulation.  
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For both cell lines there was little or no effect on p53 in  
response to 2 μM of NSC-154829, regardless of serum  
conditions (Figures 6b and 6c). The response of p21 was  
more variable. Figure 6b shows NSC-154829's effect on  
p21 in the 897/898 background. In the presence of 10%  
serum, there was a minor increase in p21 in the EGFRvIII+ 
cells when exposed to 2 μM of NSC-154829 (Figure 6b, 
lanes 1–4). This small effect was still present when the  
cells were stressed under conditions of 0.5% serum (Fig-
ure 6b, lanes 6 and 8). For the wild-type cells, under con-
ditions of 0.5% serum p21 was unchanged in response to  
NSC-154829 (Figure 6b, lanes 5 and 7). 
In the D54/54E background, levels of p21 decreased in  
both cell lines in response to drug treatment under condi-
tions of 10% serum (lanes 1–4, Figure 6c), but increased 
in both cell lines, particularly in the EGFRvIII+ cells, when 
grown in 0.5% media and then exposed to NSC-154829 
(Figure 6c, lanes 5–8). Although p21 levels were either  
increased with drug treatment, or were less down-regu-
lated in the mutant cells for the conditions studied, the  
effect was likely not large enough to account for the  
growth differences observed with NSC-154829 treatment. 
Discussion 
Glioblastoma multiforme (GBM) is the most common  
primary brain tumor with approximately 12,000 new  
cases a year in the United States [28]. Despite extensive  
research, the prognosis for GBM is poor, with a median  
survival of 10 to 12 months [29]. EGFR mutations have  
been demonstrated with a high frequency in glioblasto- 
mas with the majority of these tumors demonstrating  
increased expression of EGFR and a subset showing  
expression of the common deletion mutation EGFRvIII  
[5,6] . The latter renders these tumors resistant to radiation  
and to many of the commonly used tyrosine kinase inhib-
itors [ 12,30,31 ]. The prevalence of the EGFRvIII mutation, 
however, could prove to be a useful target for glioblasto-
mas and other tumors with this mutation.  
In this study, we used the expression of EGFRvIII to find a 
small molecule, NSC-154829, from the National Cancer 
Institutes Diversity Set, which selectively inhibits glioblas-
toma cells with this mutation, compared to glioblastoma  
cells without the mutation. Using a fluorescence-based 
screen, we found that NSC-154829 inhibits the growth of 
EGFRvIII + cells (898s), with IC50s of .27 to .59 μM com-
pared to .62 to .77 μM for wild-type cells (897s; see Table 
1). The activity across different subclones indicates that  
the inhibition is not unique merely due to particular  
genetic changes in one subclone, but instead may be due  
to changes induced by the presence of EGFRvIII. This con-
clusion is also supported by the preferential activity  
against EGFRvIII + cells from a different glioblastoma cell  
line, D54/54E. Again, IC50s for the EGFRvIII + cells  
(D54E) were significantly lower than that of the wild-type 
cells (an average of 0.33 μM for D54E compared to 0.57 
μM for D54; see Table 1). 
Supporting our screening results were trypan blue studies  
that showed the mutant cell line experiencing a dramatic  
increase in cell death following treatment with NSC- 
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154829 (Figure 4a). Hoechst staining and caspase 3/7  
studies support that this increase is due to an increase in  
apoptosis in the mutant cells lines, an effect not seen in  
the wild-type cells (Figures 4b and 5). 
Effects on downstream molecules in the EGFR pathway  
were not immediately apparent in our studies. Akt has  
received extensive attention in the literature as a possible  
target for glioblastoma therapy [24,32]. However our  
Western blot studies showed non-selective effects on Akt 
phosphorylation in both the wild-type and mutant cell  
lines (Figure 6a), which implies that NSC-154829's pref-
erence for inducing apoptosis in the EGFRvIII cells is not 
mediated through differences in Akt phosphorylation.  
NSC-154829's structure is similar to that of other purine  
analogue anti-metabolites, including compounds cur-
rently used as chemotherapeutics, such as fludarabine and 
cladribine [33,34]. Indeed these two drugs showed similar 
selectivity on our isogenic EGFRvIII lines (data not  
shown). Previous studies have shown these nucleoside  
analogues work, at least in part, by increasing apoptosis  
via up-regulation of p53 and/or p21 [35,36]. Our studies  
of p53 and p21 show no effect on p53, but show that p21  
responds differently in the mutant cells in response to  
treatment with NSC-154829. However, there is no evi-
dence for a direct molecular mechanism of action for  
NSC-154829 on the p53/p21 pathway and p21's differen-
tial response varies with cell background and serum con-
ditions. This inconsistent effect may be secondary to other  
as yet undefined genetic differences between the two gli-
oma cell lines. Overall, our experiments do not clarify the 
mechanism of NSC-154829's selective effect against  
EGFRvIII + cells and should not be interpreted as advocat-
ing a direct interaction between NSC-154829 and p21. 
It is of interest that reports on similar novel purine ana-
logues show different effects on p53 and p21. Rad-
hakrishnan and Gartel (2006) recently identified a novel  
transcriptional inhibitor, NSC-188491, which has struc-
tural similarities to NSC-154829. NSC-188491 increased 
p53 levels, but repressed p21, hdm2, and survivin [37].  
Park et al. (2006), however, found a more typical relation-
ship between p53 and p21 with MCS-C2, a novel cyclin-
dependent kinase inhibitor with structural similarities to  
NSC-154829. Treating prostate cancer cells with MCS-C2 
induced apoptosis and produced up-regulation of p53  
and p21 [38]. Thus, it would appear that the effects of  
nucleoside analogues such as NSC-154829 are mediated  
perhaps in part through the p53/p21 pathway, but these  
can vary, based on structure and/or genetic background of  
the cell line involved. Studying NSC-154829's effect on  
DNA synthesis and comparing these effects with those of 
existing purine analogues would be logical next steps.  
Literature on NSC-154829 is minimal, however the 3D  
Mind website indicates this small molecule maps to clus-
ter k18.17, a cluster that does not have a specific activity,  
but includes agents such as anti-mitotics [39]. Other small 
molecules that map to this cluster have vague structural  
similarities; none, however, were included in the diversity  
set for testing. Of those small molecules that initially  
showed selective activity against the 898 cell line, but  
which did not selectively inhibit the D54E cells (data not 
shown), NSC-321239 and NSC-75140 both had similar 
purine-type backbones to that of NSC-154829. NSC-
188491 (map location: cluster k18.13) was included in  
our diversity set and showed efficacy against EGFRvIII+  
cells in our primary screen, but did not demonstrate a sig-
nificant IC50 difference in the background of D54/54E  
(data not shown). 
The presence of EGFRvIII induces many other transcript  
and protein changes and some of these may be the critical  
steps affected by NSC-154829 [14]. The advantage to the  
screen described above is that it targets a mutation fre-
quently and almost exclusively found in GBMs, an  
approach previous glioma-centered small molecule  
screens have not exploited [32,40,41]. However, this work  
is preliminary and we acknowledge that this inhibitor is  
unlikely to act as a single therapy to overcome EGFR sign-
aling in glioblastomas because 1) drug resistance is a fre-
quent problem with single modality therapy, 2) the EGFR 
pathway can be activated at a point downstream of EGFR  
in glioblastoma, and 3) glioblastoma cell lines and  
xenografts thrive after loss of EGFRvIII. However, it is 
important to note that our approach does not find com-
pounds that directly interact with EGFRvIII, but likely tar-
get a downstream gene product induced by EGFRvIII  
pathway activation, and could lead to a therapy synergis-
tic with those that inhibit EGFR directly. For future work  
it would be useful to test NSC-154829 in combination  
with known EGFR inhibitors and/or proven glioblastoma 
therapies such as radiation. The latter may be important,  
since EGFRvIII is reported to also enhance radiation resist-
ance [12]. In addition, analogues of NSC-154829 should  
be tested to determine if its therapeutic index and drug  
delivery properties can be improved. 
Conclusion 
This study helps demonstrate the potential of cell-based 
screening to rapidly identify inhibitors of cells with a can-
cer-associated mutation. Although screens using isogenic  
cells with and without a mutation do not initially reveal  
the inhibitor's direct molecular mechanism, in our case it  
is likely that the target is related to EGFRvIII pathway acti-
vation. In theory, screens such as the one described above  
may identify compounds that are specific to a cancer-caus-
ing mutation, but at the risk of yielding a lower percentage  
of "hits" and ones with highly toxic side effects, compared 
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to traditional cell based screens [18]. Given these limita-
tions, determining in vivo efficacy and the maximum tol-
erated doses are the next steps in the investigation of NSC-
154829. Our findings suggest that NSC-154829, or  
closely related structures, should be investigated further  
for treatment of cancers with EGFR pathway activation. 
Methods 
Cell lines and plasmids 
Blue and yellow fluorescent protein (BFP and YFP, respec-
tively) expression vectors were kind gifts from Bert Vogel- 
stein and described previously [18]. The engineering of  
U87 and D54 glioblastoma cell lines either expressing  
(898, D54E) or not expressing EGFRvIII (897, D54) was  
also described previously [14]. Stable transfectants were  
created using TransfastTM (Promega, Madison, WI), and  
subclones were isolated by puromycin selection. Fluores-
cence measurements were compared between cell lines,  
and different clones were chosen based on the expression  
of equal levels of either fluorescent signal over time.  
Verification of EGFRvIII expression 
Comparative EGFRvIII expression in D54E and D54 cells  
has previously been described [14]. RNA expression of  
EGFRvIII in 898s was verified using RT-PCR and primers 
flanking the deletion site. Western blots were performed  
on cell lysates of each individual 897 and 898 clone, as  
well as lysates from the D54 and D54E cell lines to verify 
EGFRvIII protein expression (data not shown).  
Screening procedure 
The diversity set of 1,990 synthetic compounds, derived  
from a larger collection of almost 140,000 compounds,  
was obtained with permission from the Developmental  
Therapeutics Group of the National Cancer Institute [42].  
A mixture of equal amounts of 10,000 cells each of 897  
(wild-type EGFR) and 898 (EGFRvIII mutant) transfected  
with BFP or YFP, respectively, were cultured in 96 well  
plates (200 L final volume per well) containing Dul-
becco's Modified Eagle's Medium (DMEM) with 10% fetal  
calf serum and puromycin (500 ng/mL). Controls con-
sisted of wells without cells to measure background fluo- 
rescence .  Twenty- four  hours later ,  2  M of  each  
compound in DMSO was added individually to wells in  
columns 2–11; wells in column 1 received DMSO only.  
Fluorescence was measured before compound addition  
and subsequently every 24 hours for 7 days following  
compound addition, using a Genios system (Tecan Instru-
ments, Research Triangle Park, North Carolina). Absorp-
tion/emission spectra for the two fluorescent proteins  
were 390 nm absorption/510 nm emission for BFP and  
530 nm absorption/590 nm emission for YFP. This pri-
mary screen was performed in duplicate in independent  
experiments. Fluorescence data were exported into Graph- 
Pad Prism®, Version 4 (San Diego, CA) and growth curves 
were plotted. Secondary screens were performed on com-
pounds that demonstrated selective inhibition, using con- 
centrations ranging from 0.03 to 4 M. Tertiary screens  
were performed with compounds at 2 M concentration 
against two new additional subclones containing the blue  
or yellow fluorescent proteins. Both the secondary and  
tertiary screens were performed in four independent runs  
and used to calculate the mean and standard error of the  
mean for each daily fluorescence level. 
For experiments with D54 and D54E, 3,000 cells from  
each cell line were plated in individual wells of a 96 well  
plate (Day 0). The next day (Day 1), the cells were treated  
with either DMSO (HybrimaxTM, Sigma-Aldrich, St. Louis, 
MO) or with 2 M of the small molecule of interest. On  
Day 4, the media was removed, the cells were lysed with 
50 L of 0.2%SDS, incubated at 37 ° C for two hours, then 
150 L of a 1:750 solution of SYBR Green I nucleic acid 
stain (Molecular Probes, Eugene, OR) added. Fluores-
cence was measured on a Perkin Elmer Wallac 1420 Mul-
tilabel counter (Perkin Elmer, Turku, Finland) with a 485 
nm excitation filter and a 535 nm emission filter. 
Statistical analyses 
Fluorescence levels were measured daily and results aver-
aged for each day, including standard error of the mean.  
Growth curves were plotted and compared between each  
cell line with and without drug. Linear regression analysis  
was used to identify differences between 897 and 898 cell  
line growth curves in response to compound treatment,  
compared to the DMSO-only treated controls, using a p- 
value < 0.05 as the criteria for significance. IC50 values 
were determined by comparing fluorescence values for the 
898 or 897 cell lines with drug to 898 or 897 without drug 
respectively, then transforming and normalizing the data  
using GraphPad Prism. 
For experiments with D54 and D54E cells, fluorescence  
levels were measured on day 4 post drug addition and  
results averaged to give a mean and standard error of the  
mean. A non-paired T-test was performed to identify dif-
ferences in fluorescent levels between DMSO-only and 
compound-treated cells with p-values < 0.05 considered 
significant. Outliers were excluded using Grubbs' test.  
Compound purity 
The relative purities of six of the eight compounds identi-
fied as hits were assessed by HPLC (Waters 600E multisol-
vent delivery system, Milford, MA; HP Chemstation, Palo  
Alto, CA) as measured via an evaporative light-scattering 
detector (ELSD; S.E.D.E.R.E., Alfortville, France), as this 
technology does not depend on a UV-active chromo-
phore. The other two compounds, NSC-73300 and NSC-
609699, were not available in sufficient amounts for this  
test and omitted. All analyses of 30 min utilized an Inertsil 
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ODS 3 column (5 m, 4.6 X 250 mm; MetaChem Tech-
nologies, Torrence, CA). As each compound had slightly 
different chromatographic properties, individualized  
mobile phases of varying concentrations of HPLC-grade 
MeOH and H2O were developed, and the latter had either 
trifluoroacetic acid (TFA) or triethylamine (TEA) added as 
modifiers to enhance the chromatographic separations.  
Using an isocratic system 80:20 MeOH:H2O (0.1%TFA), 
NSC-177407 dissolved in MeOH had a R t of 14.2 min. 
Using an isocrat ic  system of  20:80 MeOH:H 2O  
(0.1%TFA), NSC-75140 dissolved in MeOH had a R t of 
5.6 min. Using a gradient system of MeOH:H 2O  
(0.1%TFA) that ramped from 20:80 to 80:20 over 30 min,  
NSC-154829 dissolved in H2O had a Rt of 10.9 min, and  
using the same system, NSC-321239 dissolved in DMSO  
had a R t of 14.3 min. Using a gradient system of  
MeOH:H2O (0.1%TFA) that ramped from 20:80 to 80:20  
over 20 min and was then held isocratic thereafter, NSC-
163443 dissolved in DMSO had a Rt of 23.7 min. Using an 
isocratic system of 40:60 MeOH:H2O (0.05% TEA), NSC-
100880 had a Rt of 5.0 min. 
Trypan blue studies 
100,000 cells from each cell line were plated individually  
and allowed to grow for 24 hours. NSC-154829 was 
added at a final concentration of 2 M and cells washed,   
trypsinized, and collected at appropriate time points (24,   
48, or 72 hours). The collected cells were mixed with   
trypan blue (Sigma-Aldrich, St. Louis, MO) and cell   
counts performed. 300 cells were counted for each exper-  
iment and each experiment was performed in duplicate. 
Hoechst studies 
100,000 cells from each cell line were plated individually  
and allowed to grow for the specified time periods. NSC- 
154829 was added at a final concentration of 2 M and   
then cells were washed, trypsinized, and collected at  
appropriate time points. The cells were resuspended in 40 
L of Hank's Balanced Salt Solution (Invitrogen,  
Carlsbad, CA, U.S.A.) and then mixed with 360 L of 
Hoechst solution (300 l PBS, 20 l 10% NP-40, 36 l 
37% formaldehyde and 4 l 1 mg/ml Hoechst 33258   
[Invitrogen, Carlsbad, CA, U.S.A.]). A minimum of 300   
nuclei were then evaluated using fluorescent microscopy.   
Each time point was evaluated in triplicate and increases   
in number of apoptotic nuclei were evaluated using a stu-  
dent's T-test. 
Apoptosis assays 
Apoptosis assays were performed using the Caspase-Glo® 
3/7 Assay (Promega Corporation, Madison, WI, U.S.A.)  
according to manufacturer's instructions. Briefly, 5,000  
cells were plated in 100 L media and allowed to grow for 
24 hours. NSC-154829 was then added at an appropriate 
final concentration (1, 2, 5, or 10 M). Cells were treated 
for 24 hours, and then the plates removed from the incu-
bator and allowed to equilibrate to room temperature.  
100 L of Caspase-Glo® 3/7 reagent was added to each  
well, the contents mixed, and then the plate incubated for  
1 hour at room temperature. Luminescence was measured  
on a Perkin Elmer Wallac 1420 Multilabel counter (Perkin  
Elmer, Turku, Finland) per manufacturer instructions.  
Luminescence levels of NSC-154829 treated wells were  
normalized to DMSO-treated controls and fold increases  
in caspase 3/7 levels compared using student's T-test. 
Western blotting 
40,000 cells were plated in individual wells of six-well tis-
sue culture plates, allowed to grow overnight, and then  
treated with either DMSO or appropriate concentrations  
of NSC-154829 (2, 5 or 10 M) for 24 or 96 hours. Media 
was removed, the cells were washed with 1x PBS,  
trypsinized, and collected. Cells were lysed and protein  
collected using Pierce NE-PER® Nuclear and Cytoplasmic 
Extraction Reagents (Rockford, IL, U.S.A.), following  
manufacturer's instructions. Protein extracts were quanti-
fied using the Pierce BCATM Protein Assay Kit. Equal  
amounts were loaded onto NuPage ® Novex 4–12% Bis- 
Tris gels (Invitrogen, Carlsbad, CA, U.S.A.) and electro-
phoresed for 1.5–2 hours at 80 volts. Proteins were trans-
ferred to Immunoblot PVDF membranes (Bio-Rad,  
Hercules, CA, U.S.A.), then probed with antibodies  
against phosphorylated Akt, EGFR, p53, p21 (Cell Signal-
ing Technology, Danvers, MA, U.S.A), GAPDH (Santa  
Cruz Biotechnology, Inc., Santa Cruz, CA, U.S.A), or neu-
ron specific beta-III tubulin (R&D Systems, Minneapolis,  
MN, U.S.A.). Appropriate horseradish peroxidase-conju-
gated secondary antibodies and the ECL Plus (GE Health-
care Bio-Sciences Corp., Piscataway, NJ, U.S.A.) were used 
for chemiluminescent detection. Following application of  
the chemiluminescent substrate, blots were exposed to  
Hyperfilm ECL (GE Healthcare Bio-Sciences Corp., Piscat-
away, NJ, U.S.A.) for appropriate periods of time.  
For experiments involving serum starvation, appropriate  
numbers of cells were initially plated in media with 10%  
serum, allowed to grow for 24 hours, then the media  
removed; the cells were washed, and then maintained in  
media with 0.5% serum for the duration of the experi-
ments. Cells stimulated with EGF were exposed to 100 ng/ 
mL of EGF for 15 minutes and then cells were collected,  
lysed, and protein extracted as described above.  
 
 
 
 
 
 
